Arnica montana, sometimes referred to as wolf's bane, has also been called leopard's bane, mountain tobacco and mountain arnica, is a moderately toxic ethnobotanical European flowering plant in the sunflower family. It is noted for its large yellow flower head. Unfortunately, the names "wolf's bane" and "leopard's bane" are also used for another plant, aconitum, which is extremely poisonous.
Arnica montana is a flowering plant about 18–60 cm (7.1–23.6 in) tall aromatic fragrant, perennial herb. Its basal green ovate-cilitate leaves with rounded tips are bright coloured and level to the ground. In addition, they are somewhat downy on their upper surface, veined and aggregated in rosettes. By contrast, the upper leaves are opposed, spear-shaped and smaller which is an exception within the Asteraceae. The chromosome number is 2n=38.
The flowering season is between May and August (Central Europe). The hairy flowers are composed of yellow disc florets in the center and orange-yellow ray florets at the external part. The achenes have a one-piece rough pappus which opens in dry conditions. Arnica montana is a hemicryptophyte, which helps the plant to survive the extreme overwintering condition of its habitat. In addition, Arnica forms rhizomes, which grow in a two-year cycle: the rosette part grows at its front while its tail is slowly dying.
Distribution and habitat
Arnica montana is widespread across most of Europe. It is absent from the British Isles and the Italian and Balkan peninsulas and Slovakia. In addition, it is considered extinct in Hungary and Lithuania. Arnica montana grows in nutrient-poor siliceous meadows or clay soils. It mostly grows on alpine meadows and up to nearly 3,000 m (9,800 ft). In more upland regions, it may also be found on nutrient-poor moors and heaths. However Arnica does not grow on lime soil, thus it is an extremely reliable bioindicator for nutrient poor and acidic soils. It is rare overall, but may be locally abundant. It is becoming rarer, particularly in the north of its distribution, largely due to increasingly intensive agriculture and commercial wild-crafting. Nevertheless, it is cultivated on a large scale in Estonia.
The main constituents of Arnica montana are essential oils, fatty acids, thymol, pseudoguaianolide sesquiterpene lactones and flavanone glycosides. Pseudoguaianolide sesquiterpenes constitute 0.2-0.8 % of the flower head of Arnica montana. They are the toxin helenalin and their fatty esters. 2,5-Dimethoxy-p-cymene and thymol methyl ether are the primary components of essential oils from both the plant's roots and rhizomes.
Although Amica Montana's main pharmacologically active constituent (helenalin) is safe and beneficial (as an anti-inflammatory and analgesic) in the very small quantities used in herbal medicine, it is extremely toxic and almost always fatal in larger doses. Using whole plant material can result in sudden death, and only standardized preparations of the plant should be used (sparingly) for medicinal purposes (even then, concentrated, purified, and standardized pharmaceutical-grade preparations of helenalin are considered highly preferable due to their significantly more accurate dosing and lack of pharmaceutically active minor Amica Montana alkaloids which are invariably present in plant-derived extracts).
Many of the plants trace-alkaloids are more toxic than helenalin by one or more orders of magnitude, acting as potent hepatotoxins, cytotoxins, mutagens, teratogens, and neurotoxic central nervous system stimulants.
Arnica montana is propagated from seed. Generally, 20% of seeds do not germinate. For large scale planting, it is recommended to raise plants first in a nursery and then to transplant them in the field. Seeds sprout in 14–20 days but germination rate depends highly of the seed quality. Planting density for Arnica montana is of 20 plants/m2 such that the maximum yield density will be achieved in the second flowering season. While Arnica montana has high exigencies of soil quality, analyses should be done before any fertilizer input.
Arnica montana is sometimes grown in herb gardens.
Use in herbal medicine
Historically, Arnica montana has been used as an herbal medicine for centuries. Traditional uses for the plant are similar to those for willow bark, with it generally being employed for analgesic and anti-inflammatory purposes.
Clinical trials of Arnica montana have yielded mixed results:
- When used topically in a gel at 50% concentration, A. montana was found to have the same effect when compared to a 5% ibuprofen gel for treating the symptoms of hand osteoarthritis.[non-primary source needed]
- A scientific study by FDA-funded dermatologists found that the application of topical A. montana had no better effect than a placebo in the treatment of laser-induced bruising.
- In 1998, a systematic review of homeopathic A. montana at the University of Exeter concluded that there are no rigorous clinical trials that support the claim that it is efficacious beyond a placebo effect. Similarly, a 2014 systematic review found that the available evidence did not support its effectiveness for pain, swelling, and bruises.
- A 2013 Cochrane Collaboration systematic review of topical herbal remedies for treating osteoarthritis concluded that "Arnica gel probably improves pain and function as well as non-steroidal anti-inflammatory drugs do."
The US Food and Drug Administration has classified Arnica montana as an unsafe herb because of its toxicity. It should not be taken orally or applied to broken skin where absorption can occur.
A. montana contains the toxin helenalin, which can be poisonous if large amounts of the plant are eaten or small amounts of concentrated Arnica are used. Consumption of A. montana can produce severe gastroenteritis, internal bleeding of the digestive tract, raised liver enzymes (which can indicate inflammation of the liver), nervousness, accelerated heart rate, muscular weakness, and death if enough is ingested. Contact with the plant can also cause skin irritation. In the Ames test, an extract of A. montana was found to be mutagenic.
The plant's toxicity has led to the USFDA officially declaring it to be an unsafe herb, and it is not recommended for the treatment, diagnosis, prevention, or cure of any disease or injury due to the myriad of far safer medicinal and herbal equivalents which are proven to be more effective with fewer, less severe, sequelae.
The demand for A. montana is 50 tonnes per year in Europe, but the supply does not cover the demand. The plant is rare; it is protected in Belgium, France, Germany, Italy, Poland, and in some regions of Switzerland. France and Romania produce A. montana for the international market. Changes in agriculture in Europe during the last decades have led to a decline in the occurrence of A. montana. Extensive agriculture has been replaced by intensive management.
- illustration from Franz Eugen Köhler, Köhler's Medizinal-Pflanzen, 1897
- The Plant List Arnica montana L.
- Judith Ladner. "Arnica montana". Food and Agriculture Organization. Archived from the original on February 13, 2010. Retrieved March 16, 2010.
- Arnica montana L., relevant European medical plant (2014). Waizel-Bucay J., Cruz-Juarez M. de L. Revista Mexicana de Ciencias Forestales, Vol. 5 Issue 25 p. 98-109
- "FloraWeb: Daten und Informationen zu Wildpflanzen und zur Vegetation Deutschlands". www.floraweb.de. Retrieved 2015-11-25.
- Hofmann, Maria. Heilmittel der Natur Arnika. Südwest. ISBN 3-517-08019-5.
- Archibald William Smith A Gardener's Handbook of Plant Names: Their Meanings and Origins, p. 239, at Google Books
- "Arnica montana [Arnica]". luirig.altervista.org. Retrieved 2015-11-26.
- M. Finlay, Sandra. Advance home remedies. ask1on.
- WHO Monographs of selected medicinal plants volume 3[full citation needed]
- Pljevljakušić, Dejan; Rančić, Dragana; Ristić, Mihailo; Vujisić, Ljubodrag; Radanović, Dragoja; Dajić-Stevanović, Zora (2012). "Rhizome and root yield of the cultivated Arnica montana L., chemical composition and histochemical localization of essential oil". Industrial Crops and Products. 39: 177–189. doi:10.1016/j.indcrop.2012.02.030.
- B.M.Smallfield & M.H. Douglas (2008) Arnica montana a grower‟s guide for commercial production in New Zealand. New Zealand Institute for Crop and Food Research Limited
- "Arnica". Flora of North America. efloras.org. Archived from the original on April 4, 2010. Retrieved March 16, 2010.
- A. L. Butiuc-Keul; C. Deliu (2001). "Clonal propagation of Arnica montana L., a medicinal plant". In Vitro Cellular and Development Biology – Plant. 37 (5): 581–585. JSTOR 4293517. doi:10.1007/s11627-001-0102-2.
- Knuesel, O.; Weber, M.; Suter, A. (2002). "Arnica montana gel in osteoarthritis of the knee: An open, multicenter clinical trial". Advances in Therapy. 19 (5): 209–218. PMID 12539881. doi:10.1007/BF02850361.
- R. Widrig; A. Suter; R. Saller & J. Melzer (2007). "Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study". Rheumatology International. 27 (6): 585–91. PMID 17318618. doi:10.1007/s00296-007-0304-y.
- Delilah Alonso; Melissa C. Lazarus & Leslie Baumann (2002). "Effects of topical arnica gel on post-laser treatment bruises". Dermatologic Surgery. 28 (8): 686–8. PMID 12174058. doi:10.1046/j.1524-4725.2002.02011.x. Retrieved January 27, 2008.
- Ernst, E.; Pittler, M. H. (1998). "Efficacy of Homeopathic Arnica". Archives of Surgery. 133 (11): 1187–90. PMID 9820349. doi:10.1001/archsurg.133.11.1187.
- Brito, Noe; Knipschild, Paul; Doreste-Alonso, Jorge (11 April 2014). "Systematic Review on the Efficacy of Topical for the Treatment of Pain, Swelling and Bruises". Journal of Musculoskeletal Pain. 22 (2): 216–223. doi:10.3109/10582452.2014.883012.
- "Topical herbal therapy for treating osteoarthritis | Cochrane". www.cochrane.org. Retrieved 2015-07-08.
- "Arnica". drugs.com.
- Gregory L. Tilford (1997). Edible and Medicinal Plants of the West. Mountain Press. ISBN 0-87842-359-1.
- "Final report on the safety assessment of Arnica montana extract and Arnica montana". International journal of toxicology. 20 Suppl 2: 1–11. 2001. PMID 11558636.
- "Poisonous Plants: Arnica montana". North Carolina State University.
- Rudzki E; Grzywa Z (October 1977). "Dermatitis from Arnica montana". Contact Dermatitis. 3 (5): 281–2. PMID 145351. doi:10.1111/j.1600-0536.1977.tb03682.x.
- Pasquier, B., Godin, M. (2014) L’arnica des montagnes, entre culture et cueillette. Dossier simple et aromatique, Jardins de France 630.
- Michler, B. (2007) Conservation of Eastern European Medicinal Plants Arnica Montana in Romania
|Wikimedia Commons has media related to Arnica montana.|